# DeepSynaps Clinical Intelligence OS: full public content > Clinical software for mental health and neuromodulation clinics: clinician-reviewed qEEG reports, protocol templates, patient workflow and evidence maps. Site: https://app.deepsynaps.com/. Short index: https://app.deepsynaps.com/llms.txt. Evidence snapshot 2026-09-25. ## About Availability: Phase 1 focuses on qEEG reports and approved Neuromodulation Studio templates, supported by patient management, scheduling, inbox and evidence workflows. The wider analyzer, Twin and Studio catalog shows the platform direction; access varies by capability. Clinical responsibility: The platform supports qualified professionals with review and workflow tools. It does not provide medical advice or replace independent clinical judgement. Clinicians remain responsible for clinical decisions, including neuromodulation planning and report release. ## Products ### qEEG Analyzer Page: https://app.deepsynaps.com/qeeg-analyzer/ qEEG decision-support workstation — band power, asymmetry, coherence, topographic maps, spectral markers, and longitudinal trends. Clinician review required. - Analysis methods: MNE spectral; SpecParam / Welch power; Age/sex normative z-score - Data preparation: PREP bad-channel cleaning; ICLabel artefact removal; Reference + band extraction - Accepted recordings and files: EDF, BDF, SET, CSV, PDF - Evidence and reference sources: PubMed / PMC, Cochrane, Evidence corpus, MNI / CHBMP, PhysioNet, OpenAlex - Exports: pdf, clinical summary, patient friendly, csv, json. Exports require clinician sign-off. ### Neuromodulation Studio Page: https://app.deepsynaps.com/neuromodulation-studio/ Plan TMS, tDCS, tACS and neurofeedback workflows with evidence, safety checks and clinician sign-off. - Care focus: TMS · tDCS · tACS · neurofeedback - Workflow: Drafts, safety checks and sign-off. Templates and access are reviewed for each clinic. - Workspace areas: Dashboard, Plan, Protocols, Evidence & Handbooks, Records, Twin, Safety, Programs ## Frequently asked questions ### Who is the clinical beta for? Clinicians, qEEG and neuromodulation teams, clinic owners and researchers working in mental health and neuromodulation. Developers and integration partners can also apply. Access is reviewed by the DeepSynaps team. ### What can my team explore first? Phase 1 focuses on qEEG reports and approved Neuromodulation Studio templates, supported by patient management, scheduling, inbox and evidence workflows. The wider analyzer, Twin and Studio catalog shows the platform direction; access varies by capability. ### What happens after I apply? The DeepSynaps team reviews your role, organisation and workflow, then follows up about fit and available access. Applications open access in small cohorts. Applying does not automatically create a professional account. ### Is every NERVE available now? Mental Health & Neuromodulation is the current focus. Grey specialty NERVEs show future directions. The neural map explains how data, analyzers, Twins and workspaces connect; it is an interactive product illustration, not a live model of a patient’s brain. ### Can the platform make clinical decisions for me? The platform supports qualified professionals with review and workflow tools. It does not provide medical advice or replace independent clinical judgement. Clinicians remain responsible for clinical decisions, including neuromodulation planning and report release. ### Should I include patient information in my application? No. Use the application only to describe your professional role and organisation. Do not enter patient-identifiable information on this public page. Clinical data access is handled separately through the appropriate organisation, consent and access arrangements. ### Do I need payment details to apply? No payment details are needed to apply. Beta availability, scope and any applicable commercial terms are confirmed with your team during the review process. ## Articles Index: https://app.deepsynaps.com/blog/ ### Neuromodulation research in numbers: 28 treatments and conditions compared Page: https://app.deepsynaps.com/blog/neuromodulation-research-in-numbers/ (published 2026-11-18) How much research exists for each neuromodulation treatment and condition? The DeepSynaps evidence maps count the papers tagged to 28 treatment and condition pairs in a corpus of 152,371 indexed papers (snapshot 2026-09-25). This article puts all 28 side by side. #### All 28 evidence maps at a glance Sorted by the number of papers. Each row links to its evidence map, which lists the most-cited trials and reviews with links to their sources. | Treatment and condition | Papers | RCTs | Meta-analyses | Systematic reviews | | --- | --- | --- | --- | --- | | [DBS for Parkinson’s disease](https://app.deepsynaps.com/evidence/dbs-parkinsons-disease/) | 9,164 | 242 | 154 | 201 | | [rTMS for major depressive disorder](https://app.deepsynaps.com/evidence/rtms-depression/) | 3,320 | 713 | 272 | 141 | | [VNS for refractory epilepsy](https://app.deepsynaps.com/evidence/vns-epilepsy/) | 2,111 | 65 | 52 | 72 | | [SNM for bladder and bowel dysfunction](https://app.deepsynaps.com/evidence/sacral-neuromodulation-bladder-bowel/) | 1,883 | 73 | 36 | 90 | | [DBS for refractory focal epilepsy](https://app.deepsynaps.com/evidence/dbs-epilepsy/) | 1,457 | 20 | 39 | 53 | | [DBS for essential tremor](https://app.deepsynaps.com/evidence/dbs-essential-tremor/) | 1,415 | 25 | 20 | 36 | | [tDCS for depression](https://app.deepsynaps.com/evidence/tdcs-depression/) | 1,232 | 344 | 113 | 84 | | [DBS for treatment-refractory OCD](https://app.deepsynaps.com/evidence/dbs-ocd/) | 1,171 | 24 | 34 | 54 | | [VNS for treatment-resistant depression](https://app.deepsynaps.com/evidence/vns-depression/) | 1,043 | 91 | 24 | 32 | | [RNS for focal epilepsy](https://app.deepsynaps.com/evidence/responsive-neurostimulation-epilepsy/) | 653 | 5 | 26 | 20 | | [SCS for failed back surgery syndrome](https://app.deepsynaps.com/evidence/spinal-cord-stimulation-back-pain/) | 517 | 22 | 9 | 29 | | [Deep TMS for OCD](https://app.deepsynaps.com/evidence/deep-tms-ocd/) | 491 | 82 | 42 | 29 | | [HNS for obstructive sleep apnea](https://app.deepsynaps.com/evidence/hypoglossal-nerve-stimulation-sleep-apnea/) | 424 | 9 | 15 | 13 | | [Neurofeedback for ADHD](https://app.deepsynaps.com/evidence/neurofeedback-adhd/) | 376 | 72 | 34 | 17 | | [DRG for CRPS and focal neuropathic pain](https://app.deepsynaps.com/evidence/drg-stimulation-crps/) | 352 | 7 | 7 | 25 | | [VNS for post-stroke arm rehabilitation](https://app.deepsynaps.com/evidence/vns-stroke-rehabilitation/) | 322 | 43 | 23 | 12 | | [SCS for painful diabetic neuropathy](https://app.deepsynaps.com/evidence/spinal-cord-stimulation-diabetic-neuropathy/) | 291 | 29 | 10 | 21 | | [MRgFUS for essential tremor](https://app.deepsynaps.com/evidence/focused-ultrasound-essential-tremor/) | 271 | 0 | 11 | 12 | | [Neurofeedback for anxiety and PTSD](https://app.deepsynaps.com/evidence/neurofeedback-anxiety-ptsd/) | 250 | 46 | 15 | 17 | | [BAT for heart failure](https://app.deepsynaps.com/evidence/baroreflex-activation-heart-failure/) | 163 | 7 | 8 | 3 | | [Neurofeedback for drug-resistant epilepsy](https://app.deepsynaps.com/evidence/neurofeedback-epilepsy/) | 137 | 5 | 2 | 6 | | [PBM for major depressive disorder](https://app.deepsynaps.com/evidence/photobiomodulation-depression/) | 129 | 27 | 2 | 5 | | [PNS for central sleep apnea](https://app.deepsynaps.com/evidence/phrenic-nerve-stimulation-central-sleep-apnea/) | 119 | 13 | 6 | 2 | | [nVNS for migraine and cluster headache](https://app.deepsynaps.com/evidence/nvns-migraine-cluster-headache/) | 117 | 23 | 3 | 2 | | [PBM for Alzheimer’s disease and MCI](https://app.deepsynaps.com/evidence/photobiomodulation-alzheimers/) | 77 | 13 | 1 | 8 | | [REN for migraine](https://app.deepsynaps.com/evidence/remote-electrical-neuromodulation-migraine/) | 74 | 9 | 4 | 7 | | [e-TNS for migraine](https://app.deepsynaps.com/evidence/trigeminal-nerve-stimulation-migraine/) | 65 | 6 | 4 | 4 | | [TPS for Alzheimer’s disease](https://app.deepsynaps.com/evidence/transcranial-pulse-stimulation-alzheimers/) | 59 | 8 | 4 | 3 | #### Where the randomised trials are The five maps with the most randomised controlled trials: 1. [rTMS for major depressive disorder](https://app.deepsynaps.com/evidence/rtms-depression/): 713 RCTs among 3,320 papers 2. [tDCS for depression](https://app.deepsynaps.com/evidence/tdcs-depression/): 344 RCTs among 1,232 papers 3. [DBS for Parkinson’s disease](https://app.deepsynaps.com/evidence/dbs-parkinsons-disease/): 242 RCTs among 9,164 papers 4. [VNS for treatment-resistant depression](https://app.deepsynaps.com/evidence/vns-depression/): 91 RCTs among 1,043 papers 5. [Deep TMS for OCD](https://app.deepsynaps.com/evidence/deep-tms-ocd/): 82 RCTs among 491 papers #### Fastest-growing research areas Papers published in 2021–2025 compared with 2016–2020, for maps with at least 50 papers in the earlier period: 1. [VNS for post-stroke arm rehabilitation](https://app.deepsynaps.com/evidence/vns-stroke-rehabilitation/): 52 papers in 2016–2020, 216 in 2021–2025 (4.2×) 2. [HNS for obstructive sleep apnea](https://app.deepsynaps.com/evidence/hypoglossal-nerve-stimulation-sleep-apnea/): 89 papers in 2016–2020, 266 in 2021–2025 (3.0×) 3. [Deep TMS for OCD](https://app.deepsynaps.com/evidence/deep-tms-ocd/): 98 papers in 2016–2020, 261 in 2021–2025 (2.7×) 4. [Neurofeedback for anxiety and PTSD](https://app.deepsynaps.com/evidence/neurofeedback-anxiety-ptsd/): 56 papers in 2016–2020, 144 in 2021–2025 (2.6×) 5. [VNS for treatment-resistant depression](https://app.deepsynaps.com/evidence/vns-depression/): 176 papers in 2016–2020, 437 in 2021–2025 (2.5×) #### How to read these numbers Each map counts papers tagged to that treatment and condition in the curated DeepSynaps v6 corpus; papers Jev confidently judged off-topic are excluded. Counts describe how much has been published, not how well the treatment works. Study designs are AI-classified by Jev: advisory, not clinician-reviewed. Some papers on each map have no confident study-design label yet, so the trial and review columns are lower bounds. Totals include papers from 2026, which was still in progress at the snapshot (2026-09-25). The growth comparison uses complete years only. ### Brain stimulation for depression: the research on rTMS, tDCS, VNS and PBM compared Page: https://app.deepsynaps.com/blog/brain-stimulation-for-depression-research/ (published 2026-11-18) Four neuromodulation approaches to depression have their own DeepSynaps evidence map: rTMS for major depressive disorder, tDCS for depression, VNS for treatment-resistant depression, PBM for major depressive disorder. This article compares how much research exists for each: papers, randomised trials, reviews and growth over time (snapshot 2026-09-25). #### Papers, trials and reviews | Treatment and condition | Papers | RCTs | Meta-analyses | Systematic reviews | RCT share | | --- | --- | --- | --- | --- | --- | | [rTMS for major depressive disorder](https://app.deepsynaps.com/evidence/rtms-depression/) | 3,320 | 713 | 272 | 141 | 21.5% | | [tDCS for depression](https://app.deepsynaps.com/evidence/tdcs-depression/) | 1,232 | 344 | 113 | 84 | 27.9% | | [VNS for treatment-resistant depression](https://app.deepsynaps.com/evidence/vns-depression/) | 1,043 | 91 | 24 | 32 | 8.7% | | [PBM for major depressive disorder](https://app.deepsynaps.com/evidence/photobiomodulation-depression/) | 129 | 27 | 2 | 5 | 20.9% | RCT share is the proportion of a map's papers labelled as randomised controlled trials. #### How the research has grown - [rTMS for major depressive disorder](https://app.deepsynaps.com/evidence/rtms-depression/): 694 papers in 2016–2020, 1,533 in 2021–2025 - [tDCS for depression](https://app.deepsynaps.com/evidence/tdcs-depression/): 336 papers in 2016–2020, 599 in 2021–2025 - [VNS for treatment-resistant depression](https://app.deepsynaps.com/evidence/vns-depression/): 176 papers in 2016–2020, 437 in 2021–2025 - [PBM for major depressive disorder](https://app.deepsynaps.com/evidence/photobiomodulation-depression/): 13 papers in 2016–2020, 96 in 2021–2025 #### The most-cited trial on each map - **rTMS**: [Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial.](https://pubmed.ncbi.nlm.nih.gov/29726344/) Blumberger et al., 2018. 897 citations. - **tDCS**: [The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial.](https://pubmed.ncbi.nlm.nih.gov/23389323/) Brunoni et al., 2013. 416 citations. - **VNS**: [Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.](https://pubmed.ncbi.nlm.nih.gov/16139580/) Rush et al., 2005. 370 citations. - **PBM**: [Very Low-Level Transcranial Photobiomodulation for Major Depressive Disorder: The ELATED-3 Multicenter, Randomized, Sham-Controlled Trial.](https://pubmed.ncbi.nlm.nih.gov/35950904/) Iosifescu et al., 2022. 18 citations. Citation counts measure attention in the literature, not the size or quality of an effect. #### How to read these numbers Each map counts papers tagged to that treatment and condition in the curated DeepSynaps v6 corpus; papers Jev confidently judged off-topic are excluded. Counts describe how much has been published, not how well the treatment works. Study designs are AI-classified by Jev: advisory, not clinician-reviewed. Some papers on each map have no confident study-design label yet, so the trial and review columns are lower bounds. Totals include papers from 2026, which was still in progress at the snapshot (2026-09-25). The growth comparison uses complete years only. ## Evidence maps How much research exists for each neuromodulation treatment and condition, from the curated DeepSynaps v6 corpus. Counts describe how much has been published, not how well the treatment works. Study designs are AI-classified by Jev: advisory, not clinician-reviewed. Hub: https://app.deepsynaps.com/evidence/ ### Movement disorders #### DBS for Parkinson’s disease Page: https://app.deepsynaps.com/evidence/dbs-parkinsons-disease/ 9,164 papers, including 154 meta-analyses, 201 systematic reviews and 242 randomised controlled trials. Most-cited randomised trial: A randomized trial of deep-brain stimulation for Parkinson's disease. Deuschl et al., 2006. https://pubmed.ncbi.nlm.nih.gov/16943402/ #### DBS for essential tremor Page: https://app.deepsynaps.com/evidence/dbs-essential-tremor/ 1,415 papers, including 20 meta-analyses, 36 systematic reviews and 25 randomised controlled trials. Most-cited randomised trial: A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. Schuurman et al., 2000. https://pubmed.ncbi.nlm.nih.gov/10675426/ #### MRgFUS for essential tremor Page: https://app.deepsynaps.com/evidence/focused-ultrasound-essential-tremor/ 271 papers, including 11 meta-analyses, 12 systematic reviews and 0 randomised controlled trials. ### Depression #### rTMS for major depressive disorder Page: https://app.deepsynaps.com/evidence/rtms-depression/ 3,320 papers, including 272 meta-analyses, 141 systematic reviews and 713 randomised controlled trials. Most-cited randomised trial: Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Blumberger et al., 2018. https://pubmed.ncbi.nlm.nih.gov/29726344/ #### tDCS for depression Page: https://app.deepsynaps.com/evidence/tdcs-depression/ 1,232 papers, including 113 meta-analyses, 84 systematic reviews and 344 randomised controlled trials. Most-cited randomised trial: The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. Brunoni et al., 2013. https://pubmed.ncbi.nlm.nih.gov/23389323/ #### VNS for treatment-resistant depression Page: https://app.deepsynaps.com/evidence/vns-depression/ 1,043 papers, including 24 meta-analyses, 32 systematic reviews and 91 randomised controlled trials. Most-cited randomised trial: Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Rush et al., 2005. https://pubmed.ncbi.nlm.nih.gov/16139580/ #### PBM for major depressive disorder Page: https://app.deepsynaps.com/evidence/photobiomodulation-depression/ 129 papers, including 2 meta-analyses, 5 systematic reviews and 27 randomised controlled trials. Most-cited randomised trial: Very Low-Level Transcranial Photobiomodulation for Major Depressive Disorder: The ELATED-3 Multicenter, Randomized, Sham-Controlled Trial. Iosifescu et al., 2022. https://pubmed.ncbi.nlm.nih.gov/35950904/ ### Epilepsy #### VNS for refractory epilepsy Page: https://app.deepsynaps.com/evidence/vns-epilepsy/ 2,111 papers, including 52 meta-analyses, 72 systematic reviews and 65 randomised controlled trials. Most-cited randomised trial: Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Handforth et al., 1998. https://pubmed.ncbi.nlm.nih.gov/9674777/ #### DBS for refractory focal epilepsy Page: https://app.deepsynaps.com/evidence/dbs-epilepsy/ 1,457 papers, including 39 meta-analyses, 53 systematic reviews and 20 randomised controlled trials. Most-cited randomised trial: Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Fisher et al., 2010. https://pubmed.ncbi.nlm.nih.gov/20331461/ #### RNS for focal epilepsy Page: https://app.deepsynaps.com/evidence/responsive-neurostimulation-epilepsy/ 653 papers, including 26 meta-analyses, 20 systematic reviews and 5 randomised controlled trials. Most-cited randomised trial: Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. Morrell et al., 2011. https://pubmed.ncbi.nlm.nih.gov/21917777/ #### Neurofeedback for drug-resistant epilepsy Page: https://app.deepsynaps.com/evidence/neurofeedback-epilepsy/ 137 papers, including 2 meta-analyses, 6 systematic reviews and 5 randomised controlled trials. Most-cited randomised trial: Neurofeedback impacts cognition and quality of life in pediatric focal epilepsy: An exploratory randomized double-blinded sham-controlled trial. Morales-Quezada et al., 2019. https://pubmed.ncbi.nlm.nih.gov/31707107/ ### Bladder and bowel #### SNM for bladder and bowel dysfunction Page: https://app.deepsynaps.com/evidence/sacral-neuromodulation-bladder-bowel/ 1,883 papers, including 36 meta-analyses, 90 systematic reviews and 73 randomised controlled trials. Most-cited randomised trial: Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. Schmidt et al., 1999. https://pubmed.ncbi.nlm.nih.gov/10411037/ ### OCD #### DBS for treatment-refractory OCD Page: https://app.deepsynaps.com/evidence/dbs-ocd/ 1,171 papers, including 34 meta-analyses, 54 systematic reviews and 24 randomised controlled trials. Most-cited randomised trial: Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder. Denys et al., 2010. https://pubmed.ncbi.nlm.nih.gov/20921122/ #### Deep TMS for OCD Page: https://app.deepsynaps.com/evidence/deep-tms-ocd/ 491 papers, including 42 meta-analyses, 29 systematic reviews and 82 randomised controlled trials. Most-cited randomised trial: Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Carmi et al., 2019. https://pubmed.ncbi.nlm.nih.gov/31109199/ ### Chronic pain #### SCS for failed back surgery syndrome Page: https://app.deepsynaps.com/evidence/spinal-cord-stimulation-back-pain/ 517 papers, including 9 meta-analyses, 29 systematic reviews and 22 randomised controlled trials. Most-cited randomised trial: Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicentre randomised controlled trial in patients with failed back surgery syndrome. Kumar et al., 2007. https://pubmed.ncbi.nlm.nih.gov/17845835/ #### DRG for CRPS and focal neuropathic pain Page: https://app.deepsynaps.com/evidence/drg-stimulation-crps/ 352 papers, including 7 meta-analyses, 25 systematic reviews and 7 randomised controlled trials. Most-cited randomised trial: Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Deer et al., 2017. https://pubmed.ncbi.nlm.nih.gov/28030470/ #### SCS for painful diabetic neuropathy Page: https://app.deepsynaps.com/evidence/spinal-cord-stimulation-diabetic-neuropathy/ 291 papers, including 10 meta-analyses, 21 systematic reviews and 29 randomised controlled trials. Most-cited randomised trial: Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. de Vos et al., 2014. https://pubmed.ncbi.nlm.nih.gov/25180016/ ### Sleep apnea #### HNS for obstructive sleep apnea Page: https://app.deepsynaps.com/evidence/hypoglossal-nerve-stimulation-sleep-apnea/ 424 papers, including 15 meta-analyses, 13 systematic reviews and 9 randomised controlled trials. Most-cited randomised trial: Endotypic Mechanisms of Successful Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea. Op de Beeck et al., 2021. https://pubmed.ncbi.nlm.nih.gov/32970962/ #### PNS for central sleep apnea Page: https://app.deepsynaps.com/evidence/phrenic-nerve-stimulation-central-sleep-apnea/ 119 papers, including 6 meta-analyses, 2 systematic reviews and 13 randomised controlled trials. Most-cited randomised trial: Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. Costanzo et al., 2018. https://pubmed.ncbi.nlm.nih.gov/30303611/ ### ADHD, anxiety and PTSD #### Neurofeedback for ADHD Page: https://app.deepsynaps.com/evidence/neurofeedback-adhd/ 376 papers, including 34 meta-analyses, 17 systematic reviews and 72 randomised controlled trials. Most-cited randomised trial: Is neurofeedback an efficacious treatment for ADHD? A randomised controlled clinical trial Holger Gevensleben et al., 2009. https://pubmed.ncbi.nlm.nih.gov/19207632/ #### Neurofeedback for anxiety and PTSD Page: https://app.deepsynaps.com/evidence/neurofeedback-anxiety-ptsd/ 250 papers, including 15 meta-analyses, 17 systematic reviews and 46 randomised controlled trials. Most-cited randomised trial: A Randomized Controlled Study of Neurofeedback for Chronic PTSD. van der Kolk et al., 2016. https://pubmed.ncbi.nlm.nih.gov/27992435/ ### Rehabilitation #### VNS for post-stroke arm rehabilitation Page: https://app.deepsynaps.com/evidence/vns-stroke-rehabilitation/ 322 papers, including 23 meta-analyses, 12 systematic reviews and 43 randomised controlled trials. Most-cited randomised trial: Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. Dawson et al., 2021. https://pubmed.ncbi.nlm.nih.gov/33894832/ ### Heart failure #### BAT for heart failure Page: https://app.deepsynaps.com/evidence/baroreflex-activation-heart-failure/ 163 papers, including 8 meta-analyses, 3 systematic reviews and 7 randomised controlled trials. Most-cited randomised trial: Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. Abraham et al., 2015. https://pubmed.ncbi.nlm.nih.gov/25982108/ ### Migraine and headache #### nVNS for migraine and cluster headache Page: https://app.deepsynaps.com/evidence/nvns-migraine-cluster-headache/ 117 papers, including 3 meta-analyses, 2 systematic reviews and 23 randomised controlled trials. Most-cited randomised trial: Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. Gaul et al., 2016. https://pubmed.ncbi.nlm.nih.gov/26391457/ #### REN for migraine Page: https://app.deepsynaps.com/evidence/remote-electrical-neuromodulation-migraine/ 74 papers, including 4 meta-analyses, 7 systematic reviews and 9 randomised controlled trials. Most-cited randomised trial: Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Yarnitsky et al., 2019. https://pubmed.ncbi.nlm.nih.gov/31074005/ #### e-TNS for migraine Page: https://app.deepsynaps.com/evidence/trigeminal-nerve-stimulation-migraine/ 65 papers, including 4 meta-analyses, 4 systematic reviews and 6 randomised controlled trials. Most-cited randomised trial: Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Schoenen et al., 2013. https://pubmed.ncbi.nlm.nih.gov/23390177/ ### Alzheimer’s disease and cognition #### PBM for Alzheimer’s disease and MCI Page: https://app.deepsynaps.com/evidence/photobiomodulation-alzheimers/ 77 papers, including 1 meta-analyses, 8 systematic reviews and 13 randomised controlled trials. Most-cited randomised trial: The effect of transcranial photobiomodulation on cognitive function and attentional performance of older women with mild cognitive impairment: a randomized controlled trial. Papi et al., 2022. https://pubmed.ncbi.nlm.nih.gov/36254133/ #### TPS for Alzheimer’s disease Page: https://app.deepsynaps.com/evidence/transcranial-pulse-stimulation-alzheimers/ 59 papers, including 4 meta-analyses, 3 systematic reviews and 8 randomised controlled trials. Most-cited randomised trial: Ultrasound Neuromodulation With Transcranial Pulse Stimulation in Alzheimer Disease: A Randomized Clinical Trial. Matt et al., 2025. https://pubmed.ncbi.nlm.nih.gov/40009384/ ## Other DeepSynaps sites - DeepSynaps AI Lab (https://deepsynaps.ai/): Developing AWIM, the Adaptive World Intelligence Model. - DeepSynaps Lab (https://deepsynapslab.com/): Research division building neuromorphic photonic AI chips (HAC v1 and HAC v2). - DeepSynaps Academy (https://deepsynapsacademy.com/): Seminars, workshops, online courses and consultations on neuromodulation, neuroscience and clinical AI. - DeepSynaps Türkiye (https://deepsynapsturkiye.com/): Brain mapping, clear reports and personalised follow-up in Türkiye (site in Turkish). ## Contact and policies - Contact: ali.yildirim@deepsynaps.com - Privacy Policy: https://app.deepsynaps.com/privacy/ - Terms of Service: https://app.deepsynaps.com/terms/ Decision support only. This content summarises the product and published literature; it is not medical advice or a recommendation for any patient.